$GANX - Independent research is validating GT-02287 as likely the first disease-modifying drug for Parkinson's Disease

I’ve noticed that multiple recent Parkinson’s-related papers keep pointing to the same core biology: GCase dysfunction, lipid buildup (GluSph), lysosomal failure, and downstream α-syn and autophagy problems. [One shows](https://pubmed.ncbi.nlm.nih.gov/41552855/) GluSph is elevated in GBA1 carriers even before Parkinson’s develops. [Another shows](https://academic.oup.com/hmg/article/34/24/2075/8321974?login=false) lipid imbalance directly blocks autophagy and α-syn clearance. [Another questions](https://pubmed.ncbi.nlm.nih.gov/41539444/) whether this pathway even matters in non-GBA1 PD — a question Gain has now clearly answered by showing large GluSph reductions in mostly non-GBA1 patients. None of these papers are about Gain Therapeutics' ($GANX) GT-02287. But together they keep reinforcing the same idea that lysosomal lipid stress is a key upstream player in the biology of many Parkinson’s cases. What makes GT-02287 stand out is that it doesn’t try to block one downstream interaction. It restores a core maintenance system of the neuron by fixing GCase folding and trafficking, which reduces toxic lipids, and returns lysosomal function across multiple pathways. ER stress and returning mitochondrial should also improve according to pre-clinical models and independent research. The recent share price is completely disconnected from reality. There are no disease-modifying therapies for Parkinson’s. None. GT-02287 has proven every step of the way that they are likely to be the first, and likely the best (by far). That’s why I added a lot to my position recently. I think they have shown that they have a drug that works, and I think they have data that they are waiting to release at AD/PD. I would never suggest buying more than you can afford to lose, but I don’t think there is better time to start a position or average down. I think the next few months are going to be very interesting.